{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '2.1', 'Schedule of Assessments', 'Open-Label Treatment Period 1', 'Follow-Up Period 2', 'Follow-Up Contact 3', '(24 Weeks)', '(24 weeks)', '(48 Weeks)', '11/', 'FU3/', 'Study Visit', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'FU1', 'FU2', 'FU4', 'FU5', 'FU4', 'FU5', 'PW4', 'PW5', 'Week (W)/', 'Day 16', 'W1', 'W3', 'W4/', 'W6', 'W9', 'W12/', 'W15', 'W18', 'W21', 'W24/', 'W28/', 'W36/', 'W48/', 'W48/', 'W72/', 'W72/', 'W96/', 'Month (M)', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M12', 'M18', 'M18', 'M24', 'Visit Window ( days)', '(+147', '(+1)', '(+3)', '(+1)', '(+3)', '(+3)', '(+3)', '(+3)', '(+3)', '(+3)', '(+7)', '(+7)', '(+7)', '(+7)', '(+14)', '(+14)', '(+14)', '(+14)', 'Proptosis', 'Subject response in', 'Proptosis Non-responder or Relapse', 'Proptosis Non-responder', 'Study HZNP-TEP-301', 'Relapse Only', 'Non-responder', 'Only', 'Only', 'Informed Consent', 'X', 'Review inc/exc criteria', 'X', 'Weight 8', 'X9', 'X', 'X', 'Study drug infusion 10', 'X', 'Phone (email) contact for safety', '24 hours postdose 11', 'Investigator assessment of active', 'X', 'X', 'X', 'X', 'disease', 'Efficacy assessments', 'CAS', 'X9', 'X', 'X', 'X', 'X', 'X', 'Clinical Measures of Severity', '- includes proptosis, diplopia,', 'X9', 'X', 'X', 'X', 'X', 'X', 'X', 'and motility restriction', 'Safety assessments', 'Pregnancy Test 12', 'X9', 'X', 'X', 'X', 'X', 'Physical exam 13', 'X9,13', 'X13', 'X13', 'Ophthalmic exam 14', 'X9', 'X', 'X', 'X', 'Vital Signs 15', 'X9', 'X', 'X', 'X', 'X', '12-Lead ECG', 'X9', 'X', 'Clinical laboratory tests 16', 'Chemistry (excl. glucose)', 'X9,17', 'X', 'X', 'Thyroid (FT3, FT4, TSH) 18', 'x9', 'X', 'X', 'X', 'X', 'X', 'Hematology', 'X9', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 35 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Open-Label Treatment Period 1', 'Follow-Up Period 2', 'Follow-Up Contact\u00b3', '(24 Weeks)', '(24 weeks)', '(48 Weeks)', '11/', 'FU3/', 'Study Visit', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'FU1', 'FU2', 'FU4', 'FU5', 'FU4', 'FU5', 'PW4', 'PW5', 'Week (W)/', 'Day 16', 'W1', 'W3', 'W4/', 'W6', 'W9', 'W12/', 'W15', 'W18', 'W21', 'W24/', 'W28/', 'W36/', 'W48/', 'W48/', 'W72/', 'W72/', 'W96/', 'Month (M)', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M12', 'M18', 'M18', 'M24', 'Visit Window ( days)', '(+147', '(+1)', '(=3)', '(+1)', '(+3)', '(+3)', '(+3)', '(+3)', '(+3)', '(+3)', '(+7)', '(+7)', '(+7)', '(+7)', '(+14)', '(+14)', '(+14)', '(+14)', 'Proptosis', 'Subject response in', 'Proptosis Non-responder or Relapse', 'Proptosis Non-responder', 'Relapse Only', 'Non-responder', 'Study HZNP-TEP-301', 'Only', 'Only', 'Glucose\u00b9 19', 'X9', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'HbAlc', 'X9', 'X', 'X', 'Urinalysis', 'X9', 'X', 'X', 'X', 'X', 'ADA/NAb samples 20', 'X9', 'X\u00b21', 'X', 'AE, SAE assessment 22', 'X9', 'X', 'X', 'X', 'X', 'Concomitant medications', 'X9', 'X', 'GO-QoL Questionnaire', 'X9', 'X', 'PK samples 23', 'X', 'X21', 'Contact (phone/email) to assess', 'X', 'X', 'X', 'X', 'additional TED treatment 24', 'ADA=anti-drug', 'antibody; AE=adverse event; CAS=Clinical Activity Score; ECG=electrocardiogram; FT3=free triiodothyronine; FT4=free thyroxine; FU=Follow-Up;', \"GO-QoL=Graves' Ophthalmopathy Quality of Life Questionnaire; HbAlc=glycated hemoglobin; M=month; NAb=neutralizing antibody; PK=pharmacokinetic; PW=premature\", 'withdrawal; SAE=serious adverse event; TED=thyroid eye disease; TSH=thyroid stimulating hormone; W=week.', 'Footnotes:', '1. Open-label Treatment Period. Subjects with TED who are proptosis non-responders at Week 24 of HZNP-TEP-301 or were proptosis responders at Week 24 but who meet', 'criteria for re-treatment due to relapse during the Follow-Up Period in HZNP-TEP-301 are eligible to enroll and receive 8 infusions of teprotumumab (10 mg/kg for the first', 'infusion titrated to 20 mg/kg for the remaining infusions) in an open-label fashion.', '2.', 'Proptosis non-responders from Study HZNP-TEP-301 will participate in a 6-month Follow-Up Period; subjects who relapsed during the Follow-Up Period of HZNP-TEP-301', 'will not participate.', '3. Proptosis non-responders from Study HZNP-TEP-301 who complete the Month 12 Visit and subjects who relapsed during the Follow-Up Period of HZNP-TEP-301 and', 'complete the Week 24 Visit will be contacted via phone or email by research staff to enquire if any treatment for TED has been received since last study contact.', '4. If subjects wish to discontinue study drug during the open-label Treatment Period, subjects will return for a clinic visit and undergo the Week 24 assessments, except for PK', 'and ADA evaluations. Subjects who were proptosis non-responders at Week 24 of HZNP-TEP-301 will be encouraged to continue study participation in the Follow-Up Period.', '5. If a subject wishes to prematurely discontinue from the study during the Follow-Up Period, he/she will return for a clinic visit and undergo the Month 12 assessments prior to', 'discharge.', '6. On Day 1 (Baseline), subjects will receive the first dose of study drug; however, Baseline assessments will be performed prior to dosing.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 36 of 118']\n\n###\n\n", "completion": "END"}